舌下与皮下特异性免疫治疗在儿童变应性鼻炎治疗中的疗效与安全性比较

doi:10.3969/j.issn.1671-7171.2026.01.027

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1162 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To compare the efficacy and safety of sublingual specific immunotherapy(SLIT) and subcutaneous specific immunotherapy(SCIT) in children with allergic rhinitis.【Methods】 A total of 102 children with dust mite-induced allergic rhinitis admitted to our hospital from January 2022 to May 2024 were selected as research subjects, and divided into an observation group(treated with SLIT) and a control group(treated with SCIT) using the random number table method, with 51 cases in each group. The total nasal symptom score(TNSS) and visual analogue scale(VAS) score of the two groups before treatment and 1 year after treatment were compared, as well as the total medication score(TMS), total treatment cost, incidence of adverse reactions and treatment dropout rate of the two groups after 1 year of treatment.【Results】 One year after treatment, the TNSS and VAS scores of both groups were lower than those before treatment, with statistically significant differences(P<0.05), but there were no statistically significant differences in TNSS and VAS scores between the two groups(P>0.05). One year after treatment, the TMS of the observation group was higher than that of the control group, while the total treatment cost, total incidence of adverse reactions and total treatment dropout rate of the observation group were lower than those of the control group, with statistically significant differences(P<0.05).【Conclusion】 SLIT and SCIT have comparable efficacy in improving the symptoms of allergic rhinitis in children, but SLIT has higher safety, better compliance and lower cost, making it more suitable as the preferred clinical desensitization regimen. It provides practical evidence for standardized desensitization treatment of allergic rhinitis in children.

Key words： Rhinitis, Allergic, Perennial Administration, Sublingual Desensitization, Immunologic

Received: 30 May 2025

PACS:

R765.213

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Jian
	TANG Meiling
	XU Xiaohua

Cite this article:

WANG Jian,TANG Meiling,XU Xiaohua. Efficacy and Safety Comparison of Sublingual and Subcutaneous Specific Immunotherapy in Children with Allergic Rhinitis[J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(1): 95-98.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2026.01.027 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2026/V43/I1/95

[1] 谭国林. 难治性变应性鼻炎的外科治疗现状[J].医学临床研究,2021,38(3):321-325.
[2] 韩学丽,刘晓玲. 儿童变应性鼻炎影响因素研究进展[J].中华预防医学杂志,2024,58(2):196-201.
[3] 邓晓园,王国蓉,张甜,等. 18岁以下人群变应性鼻炎患病率的Meta分析[J].护理实践与研究,2023,20(10):1550-1557.
[4] 李婧怡,李昱剑,赖晟琳,等. N6-腺苷酸甲基化和铁死亡在儿童变应性鼻炎-哮喘综合征中的研究进展[J].中国当代儿科杂志,2025,27(2):242-246.
[5] 王洪田,杨钦泰,叶菁,等. 变应性鼻炎防治中环境控制和健康教育的中国专家共识(2024,北京)[J].中国耳鼻咽喉颅底外科杂志,2024,30(4):1-11.
[6] 卢蓉蓉,张兰,郑洁,等. 过敏原特异性免疫治疗在变应性鼻炎伴哮喘治疗中的临床疗效[J].医学研究杂志,2023,52(4):138-147.
[7] 庄仕杰,范婷婷,阮欣妤,等. 2021—2024年深圳市某儿童医院变应性鼻炎和哮喘儿童屋尘螨组分分布特征的分析[J].中华预防医学杂志,2024,58(12):1885-1893.
[8] 娄鸿飞,张罗. 中国变应性鼻炎过敏原特异性免疫治疗现状及展望[J].中华耳鼻咽喉头颈外科杂志,2022,57(4):385-391.
[9] 中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组,中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 变应性鼻炎诊断和治疗指南(2015年,天津)[J].中华耳鼻咽喉头颈外科杂志,2016,51(1):6-24.
[10] 向莉,赵京,鲍一笑,等. 儿童气道过敏性疾病螨特异性免疫治疗专家共识[J].中华实用儿科临床杂志,2018,33(16):1215-1223.
[11] 王学艳,任华丽,石海云,等. 变应性鼻炎症状评分及视觉模拟量表适用性比较[J].中国耳鼻咽喉头颈外科,2012,19(11):609-611.
[12] 中华耳鼻咽喉头颈外科杂志编委会鼻科组,中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 变应性鼻炎特异性免疫治疗专家共识[J].中华耳鼻咽喉头颈外科杂志,2011,46(12):976980.
[13] 唐识明,贾昕,苏亮,等. 皮下特异性免疫治疗和舌下特异性免疫治疗尘螨过敏性哮喘伴变应性鼻炎患儿的效果及安全性对比[J].中国妇幼保健,2024,39(4):625-628.
[14] 符文婷. 变应性鼻炎皮下特异性免疫治疗的疗效及安全性研究[D]. 扬州:扬州大学,2023.
[15] 冯仙,刘娟. 变应性鼻炎皮下特异性免疫治疗中断的原因分析及对策[J].中国眼耳鼻喉科杂志,2022,22(3):232-235.